Mr. Rongen is the Chief Executive Officer and a Co-Founder of Matinas BioPharma. He is also the Founder and Chairman of Essential Fatty Acid Therapeutics, a biotech company focused on the development of innovative fatty acid derivatives. Prior to Matinas BioPharma, Mr. Rongen was Executive Vice President North American Operations for EPAX/Trygg Pharma and Vice President of Life Cycle Management and Intellectual Property at Reliant Pharmaceuticals, a GlaxoSmithKline subsidiary. While at Reliant, Mr. Rongen held various earlier positions, including head of the Omacor®/Lovaza® launch team, Executive Director of Marketing for Lescol® and Executive Director of Business Development. Before Reliant, Mr. Rongen was Global Product Director for Humira® at BASF Pharmaceuticals, later acquired by Abbott. He was also a consultant at The Wilkerson Group in New York and with Arthur D. Little in Amsterdam. Mr. Rongen earned an MBA from Kellogg GSM at Northwestern University, and a graduate degree in Molecular Sciences from Wageningen Univerisity in the Netherlands.

Recent Posts

Forward Looking Statements

Materials on this website may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect our business, particularly those identified in the risk factor and cautionary factors discussions in our SEC filings. In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. We specifically disclaim obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date.

This Blog is official and sanctioned by Matinas BioPharma Holdings | See Forward Looking Statements | See Privacy Policy | See Terms of Use

Get Matinas BioPharma Holdings Blog Post Alerts